– Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events…
– Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events…
Transaction and reduction in operating expenses enhance Mustang’s cash position WORCESTER, Mass., July 31, 2023…
Transaction and reduction in operating expenses enhance Mustang’s cash position WORCESTER, Mass., July 31, 2023…
Patent Filing Follows Year of Preclinical Research, Academic Publication VANCOUVER, British Columbia, July 31, 2023…
Patent Filing Follows Year of Preclinical Research, Academic Publication VANCOUVER, British Columbia, July 31, 2023…
Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ET NEW YORK,…
Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ET NEW YORK,…
LEXINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in…
LEXINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in…
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q…
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q…
Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern Time SAN DIEGO, July…
Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern Time SAN DIEGO, July…
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”)…
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”)…